Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyquaternium-42 is a cationic polymer belonging to the polyquaternium class of chemicals, primarily utilized as an antimicrobial preservative in ophthalmic formulations and personal care products. It is chemically categorized as a polyquaternary ammonium compound. In clinical research, specifically in studies sponsored by Johnson & Johnson, it has been evaluated as an experimental preservative for over-the-counter (OTC) lubricant eye drops (containing ingredients such as glycerin, hypromellose, and polyethylene glycol 400) intended for the treatment of dry eye. Its mechanism of action relies on its positive charge, which allows it to electrostatically bind to and disrupt the negatively charged cell membranes of bacteria and fungi, thereby maintaining the sterility of multi-dose pharmaceutical products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyquaternium-42.